{
  "id": 7524888,
  "title": "QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases",
  "url": "https://urgent.news/2026/09/15/qurcan-therapeutics-enters-strategic-research-and-collaboration",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-15T10:01:31.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/qurcan-therapeutics-enters-strategic-research-and-collaboration-agreement-with-lilly-to-advance-nucleic-acid-therapies-for-central-and-peripheral-nervous-system-diseases"
  },
  "original_language": "en",
  "account": null,
  "summary": "Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platform Lilly to make a strategic investment in QurCan TORONTO — QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}